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We investigated large vessel function in lean Goto-Kakizaki diabetic rats (GK) and Otsuka Long-Evans Tokushima Fatty
diabetic rats (OLETF) with possible roles of hyperglycemia/hyperosmolarity and insulin. Both young and old GK showed
marked hyperglycemia with normal insulin level and well-preserved endothelium-dependent and endothelium-independent
vasodilation in aorta and carotid artery. There were signiﬁcant elevations in endothelial/inducible nitric oxide synthase
(eNOS/iNOS) and inducible/constitutive heme oxygenase (HO-1/HO-2) in GK. The endothelium-dependent vasodilation in GK
was inhibited partly by NOS blockade and completely by simultaneous blocking of HO and NOS. In contrast, OLETF showed
hyperinsulinemia and mild hyperglycemia but signiﬁcant endothelium dysfunction beginning at early ages with concomitantly
reduced eNOS. Insulin injection corrected hyperglycemia in GK but induced endothelium dysfunction and intima hyperplasia.
Hyperglycemia/hyperosmolarityin vitro enhanced vessel eNOS/HO. We suggest that hyperinsulinemia plays a role in endothelium
dysfunction in obese diabetic OLETF, while hyperglycemia/hyperosmolarity-induced eNOS/HO upregulation participates in the
adaptation of endothelium function in lean diabetic GK.
1.Introduction
It is well established that type 2 diabetes is associated
withincreasedmacro-andmicrovascularcomplications.Hy-
perglycemia, the main characteristic of both type 1 and type
2 diabetes, is generally considered a detrimental factor in
vascular dysfunction and therefore, diabetic patient treat-
ment has focused primarily on tight blood glucose control.
However, recent evidence from the most relevant clinical
trials aiming at improving cardiovascular outcomes with in-
tensive glycemic control does not support the assumption
that strict glucose control exclusively is suﬃcient to reduce
cardiovascular risk in complicated type 2 diabetes, ques-
tioning the role of hyperglycemia in poor cardiovascular
outcomes [1–3].
Beside the debate in clinical settings, there are also con-
troversiesovertheroleofhyperglycemiainendotheliumdys-
function and cardiovascular tolerance to ischemia in diabetic
animals [4–9]. We have found that streptozotocin-induced
type 1 diabetic rats demonstrated well-preserved coronary
ﬂow reservation after myocardial ischemia in vitro as well
as unchanged or even slightly enhanced endothelium-de-
pendent vasodilation in isolated aorta [6, 7]. We also
found that hyperglycemia/hyperosmolarity could induce2 Experimental Diabetes Research
endogenous antioxidants including heme oxygenase (HO) in
cardiovascular system that may contribute to the preserved
vessel function in diabetes with severe hyperglycemia [6, 7,
10, 11]. There are other investigations showing unaltered or
augmentedendothelium-dependentrelaxationatearlystages
oftype1andtype2diabeticrats[12–15],indicatingdiﬀerent
mechanisms involved in the two types of diabetes.
Goto-Kakizaki rats (GK) are a highly inbred strain of
glucose-intolerant Wistar rats that spontaneously develop
type 2 diabetes without obesity [16]. Another kind of type
2 diabetic rats, Otsuka Long-Evans Tokushima Fatty rats
(OLETF), are a strain of rats that develop hyperglycemia
g r a d u a l l ya f t e rb i r t hw i t ho b e s i t y[ 17], resembling human
type 2 diabetes with obesity. Our previous studies revealed
decreased coronary ﬂow after ischemia [18] and basal en-
dothelium dysfunction [10] in 6- to 12-month-old OLETF.
However, endothelium function may vary depending
on different site of vascular beds, various stages, and severity
of diabetes. And there is little investigation comparing
large vessel function between diabetic rats of lean GK and
obese OLETF at diﬀerent stages. Therefore, we designed to
compare vasodilation changes of aorta and carotid artery in
diabeticleanGKandobeseOLETFatearlyandlaterstagesof
diabetes. We also checked the eﬀect of metabolic control on
vessel function and intima with insulin injection in GK that
had higher glucose but relatively normal insulin levels. The
possible roles of NOS and HO in the endothelium function
as well as the eﬀects of hyperglycemia/hyperosmolarity on
vessel eNOS/HO-1 were investigated.
2. Methods
2.1. Animals. All experimental procedures were performed
under protocols approved by the Animal Care Committee
of the Animal Center at the Chinese Academy of Sciences
in Shanghai and by the Committee on the Care and Use of
Animals in Research at Shanghai Jiao Tong University/Kinki
University School of Medicine in Japan.
Male GK and normal control Wistar rats at 3, 6, and 12
months of age were obtained from the Shanghai Laboratory
Animal Center, Chinese Academy of Science. Male OLETF
and nondiabetic control Long-Evans Tokushima Otsuka rats
(LETO) at 2 months of age were supplied by the Tokushima
Research Institute (Otsuka Pharmaceutical, Tokushima, Ja-
pan) and raised in the animal center of Kinki University
School of Medicine, up to the same ages of GK until sacriﬁce.
T h ea n i m a l sw e r eh o u s e di nt w op e rc a g ei nat e m p e r a t u r e -
controlled room with a 12:12-h light-dark cycle and had
water and rat chow ad libitum.
2.2.BloodPressureMeasurement. Systolicbloodpressureand
heart rate were measured in conscious state with tail-cuff
method using a blood pressure analyzer (BP-98A, Softron,
Beijing, China) before vessel tension experiment.
2.3. Biochemical Determinations. Blood samples were col-
lected for biochemical determination at the time of sacriﬁce.
Blood lipids were measured using a biochemistry auto-
matic analyzer (Hitachi, Tokyo, Japan). Serum insulin was
determined with a rat radioimmunoassay insulin kit (Linco
Research, St. Charles, USA).
2.4. Assessment of Vessel Function. The method of vascular
tension recording was modiﬁed slightly from our previous
description [7, 10]. Brieﬂy, after anesthesia, the thoracic
aorta and common carotid artery were dissected carefully,
cleaned of fat and adherent connective tissues, cut into seg-
mentsof2to3mm(aorta)and1to2mm(carotid)inlength,
and mounted on two stainless-steel stirrups in 10mL organ
chambers with Krebs’-Henseleit buﬀer (KHB) containing
(in mmol/L): NaCl 118.0, KCl 4.7, CaCl2 2.5, MgSO4 1.2,
KH2PO4 1.2, NaHCO3 25.0, glucose 11.0, and Na2-EDTA
0.5, at 37◦C. One stirrup was connected to an isometric force
transducer for tension measurement in organ bath (ALC-
B10organbathsystem,AlcottBiotech,Shanghai,China)and
recorded with a data-acquisition system (MPA 2000, Alcott
Biotech).
The artery rings were stretched to a resting tension of
2.0g (aorta) and 1.0g (carotid), respectively, and allowed to
equilibratefor40to50min,withthebuﬀerchangedevery10
to15min.Thecontractionresponsewasevaluatedtwicewith
60mmol/L of KCl obtained by substituting an equimolar
amount of KCl for NaCl in KHB. Endothelium function was
assessed by 1μmol/L acetylcholine (ACh) when a contractile
plateau was reached after 1μmol/L phenylephrine. Then,
dose-response contraction to cumulative phenylephrine and
dilation to acetylcholine (ACh)/sodium nitroprusside (SNP)
were examined, increasing agent concentration at every 3
minute.
To investigate possible mechanisms responsible for en-
dothelium-dependent vasodilation, the rings were further
incubated with NOS inhibitor Nω-nitro-L-arginine methyl
ester (L-NAME; 100μmol/L, 30min) and HO inhibitor
protoporphyrin IX zinc (II) (ZnPPIX; 2μmol/L, 30min).
ACh-induced dilation was reexamined after NOS and HO
blockade.
2.5. Immunoﬂuorescence Study. Aortic and carotid segments
of GK or OLETF with their respective controls at 12 months
of age were immersed in 10% polyformaldehyde, embedded
in paraﬃn, and sectioned for immunoﬂuorescence col-
ocalization of eNOS/iNOS and HO-1/HO-2. For double im-
munoﬂuorescence reactions, sections were incubated in a
mixture of primary antibodies including a monoclonal anti-
eNOS antibody (1:1000 dilution; Sigma, St. Louis, MO,
USA) and a polyclonal anti-iNOS antibody (1:100 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), or in
a mixture of primary antibodies including a monoclonal
anti-HO-1 antibody (1:100 dilution; Stressgen, Victoria,
BC, Canada) and a monoclonal anti-HO-2 antibody (1:400
dilution; Assay Designs, Ann Arbor, MI, USA) [10, 19]. After
incubation with the primary antibodies overnight at 4◦C,
sections were rinsed three times, followed by incubation
with streptavidin-ﬂuorescein isothiocyanate-conjugated andExperimental Diabetes Research 3
tetramethylrhodamine isothiocyanate-conjugated secondary
antibodies for 30min in a light-protected humidiﬁed cham-
ber.ThesectionswerethenwashedwithPBS,andﬂuorescent
eNOS/iNOS or HO-1/HO-2 was observed under a confocal
microscope (Leica TCS SP2 Microsystems, Heidelberg, Ger-
many).
Digital images were captured and imported into JPEG
ﬁles, and the areas of respective red and green ﬂuorescence
intensities (scale units ranging from 0 to 255, absolute red or
green to absolute black) of intima were analyzed individually
using Image-Pro Plus 5.0 software (Media Cybernetics,
Bethesda, MD, USA). The obtained mean intensity for each
image was inverted, with values of brighter color being
higher, and divided by the respective area. The mean values
in diﬀerent groups were then compared with respective
c o n t r o lv a l u e sa sr e f e r e n c e[ 19].
2.6. Insulin Administration. One group of GK at 12 months
were injected with protamine zinc insulin from 20 to
25IU/kg/d subcutaneously for metabolic correction for 20d
before in vitro vessel function and morphology examination
of aorta and carotid with transmission electron microscopy
(TEM) as described before [10]. Blood glucose level was
tested every other day and 5 to 6 days were necessary for
achieving a relatively stable metabolic control. Therefore, the
total insulin administration duration was from 25 to 26 days
before vessel examination.
2.7. Measurement of Vessel Nitric Oxide (NO) and Reactive
Oxygen Species (ROS). Aortic tissues of Wistar rats, GK,
and insulin-injected GK of 12 months were used for
in vitro measurement of NO and ROS production. To
measure intracellular NO production, the membrane-per-
meable ﬂuorescent indicator 4-amino-5-methylamino-2 ,
7 -diﬂuoroﬂuorescein diacetate (DAF-FM), was used.
Brieﬂy, aortic rings were loaded with 5μmol/L DAF-FM
for 30min at 37◦C and ﬂuorescence was measured at an
excitationwavelengthof485nmandanemissionwavelength
of 538nm every 1min for 30min [20]. Intracellular levels of
ROS production were determined by measuring oxidative
conversion of cell permeable 2 ,7  -dichloroﬂuorescein di-
acetate into ﬂuorescent dichloroﬂuorescein, which was de-
tected by ﬂuorospectrophotometer at an excitation wave-
length of 488nm and an emission wave length of 535nm
[21].
2.8. Hyperglycemia/Hyperosmolarity Incubation and West-
ern Blotting. A o r t ar i n g sf r o mn o r m a lW i s t a rr a t sw e r e
incubated in vitro with hyperglycemia/hyperosmolarity by
adding extra glucose or mannitol (50mmol/L) into normal
KHB with a ﬁnal osmolarity of 350mOsm/L [10]. After
5h incubation with hyperglycemia/hyperosmolarity, the ves-
sel rings were homogenized in lysis buﬀer (50mmol/L β-
glycerophosphate, 100mmol/L Na3VO4, 2mmol/L MgCl2,
1mmol/L EGTA, 0.5% Triton X-100, and 1mmol/L
DTT) containing protease inhibitors (20mmol/L pepstatin,
20mmol/L leupeptin, 1,000U/mL aprotinin, and 1mmol/L
phenylmethylsulfonyl ﬂuoride). The soluble lysates were
subjected to 10% (w/v) SDS-PAGE; proteins were then
transferred to nitrocellulose membranes and blocked with
5% (w/v) nonfat milk/Tris-buﬀered saline Tween 20 (TBST)
for 1h at room temperature. Membranes were incubated
overnight at 4◦C with primary antibodies against tubulin
(1:5000; Sigma), eNOS (1:1000; Sigma), or HO-1 (1:1000;
Stressgen) in 5% (w/v) milk/TBST [10, 19]. The membranes
were washed three times with TBST and then incubated with
correspondinghorseradishperoxidase-conjugatedsecondary
antibody for 1h, and immunoreactive bands were visualized
using chemoluminescence. The relative protein levels were
semiquantiﬁed with scanning densitometry and normalized
against tubulin.
2.9. Statistical Analysis. Data are presented as mean ± SEM.
Diﬀerences in body weight, blood pressure, glucose, insulin,
and other biochemical parameters among groups were
analyzed with ANOVA followed by Student-Newman-Keuls
post hoc analysis. Repeated measurement ANOVA was used
forconcentration-responserelation.Signiﬁcancewasdeﬁned
as P<0.05.
3. Results
3.1. Basic Data. As shown in Figure 1,b o t hG Ka n dO L E T F
had signiﬁcantly elevated glucose, with the level of GK
higher than that of OLETF. The insulin levels in GK were
identicaltotheirnormalcontrolat3and12months,whereas
OLETF had early increase in insulin which was maintained
until middle age and declined at 12 months as compared
with control LETO. Higher LDL-cholesterol and triglyceride
levels were present in OLETF. However, GK showed higher
HDL-cholesterol without elevation of LDL-cholesterol and
triglyceride. The other basic data of GK and OLETF are
shown in Tables 1 and 2. Besides normal blood pressure, GK
showed increased heart rate at early and later stages.
3.2. Vessel Relaxation. In GK at 3 and 12 months, both
ACh- and SNP-induced dilation was signiﬁcantly enhanced
in aorta and carotid artery (Figure 2). The OLETF vessels, on
the contrary, had signiﬁcant impairment in ACh- and SNP-
inducedaorticdilationat3and12monthswithendothelium
dysfunction of carotid artery at later stage (Figure 3).
As demonstrated in Figure 4, NOS blocker L-NAME
(100μmol/L) could abolish ACh-induced aortic dilation in
normal control but ACh-induced dilation in GK remained
about 6% after NOS inhibition. This non-NO-dependent
dilation could not be abrogated by indomethacin but could
be abrogated by HO blockade with ZnPPIX (2μmol/L) in
the presence of L-NAME (100μmol/L), indicating NOS- and
HO-related vasodilation. Carotid dilation induced by ACh
could be abrogated completely by NOS blockade in both
GK and OLETF, demonstrating NOS-related vasodilation in
carotid artery without HO participation.
3.3. Vessel NOS and HO. Immunoﬂuorescence examina-
tion demonstrated increased protein expression of aortic
eNOS/iNOS and HO-1/HO-2 in GK, especially in the4 Experimental Diabetes Research
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Figure 1: Blood glucose and insulin levels in Goto-Kakizaki rats (GK) and Otsuka Long-Evans Tokushima Fatty rats (OLETF). LETO: Long-
Evans Tokushima Otsuka rats. Wistar is the control for GK, and LETO is the control for OLETF. Data are mean ± SEM, n = 8. ∗P<0.05,
∗∗P<0.01 versus respective controls, ††P<0.01 versus respective GK or OLETF at 3 months.
Table 1: Basic data of Wistar control and diabetic Goto-Kakizaki rats (GK).
3m o n t h s 1 2m o n t h s
Wistar GK Wistar GK
Body weight (BW), g 365 ±8 307 ±7∗∗ 498 ±9 409 ±10∗∗
Systolic blood pressure, mmHg 115 ±6 117 ±7 118 ±8 119 ±5
Heart rate, beat/min 380 ±8 439 ±5∗∗ 382 ±7 455 ±12∗∗
Total cholesterol, mmoL/L 1.82 ±0.05 2.94 ±0.11∗∗ 2.63 ±0.13 3.11 ±0.08∗∗
LDL-cholesterol, mmoL/L 0.44 ±0.02 0.40 ±0.02 0.58 ±0.07 0.55 ±0.02
HDL-cholesterol, mmoL/L 1.13 ±0.03 2.48 ±0.09∗∗ 1.73 ±0.08 2.49 ±0.08∗∗
Triglyceride, mmoL/L 1.19 ±0.16 1.20 ±0.14 1.86 ±0.07 1.65 ±0.13
∗P<0.05, ∗∗P<0.01 versus respective age-matched Wistar controls. Data are mean ± SEM, n = 8.Experimental Diabetes Research 5
Table 2: Basic data of nondiabetic control Long-Evans Tokushima Otsuka rats (LETO) and diabetic Otsuka Long-Evans Tokushima Fatty
rats (OLETF).
3m o n t h s 1 2m o n t h s
LETO OLETF LETO OLETF
Body weight (BW), g 377 ±6 478 ±8∗∗ 678 ±26 659 ±32
Systolic blood pressure, mmHg 155 ±12 145 ±5 148 ±5 150 ±3
Heart rate, beat/min 406 ±12 411 ±16 358 ±6 383 ±14
Total cholesterol, mmoL/L 1.97 ±0.06 2.35 ±0.08∗∗ 3.13 ±0.19 5.88 ±0.64∗∗
LDL-cholesterol, mmoL/L 0.13 ±0.01 0.14 ±0.01 0.25 ±0.02 0.69 ±0.12∗∗
HDL-cholesterol, mmoL/L 0.77 ±0.02 0.94 ±0.03∗∗ 0.87 ±0.04 1.43 ±0.14∗∗
Triglyceride, mmoL/L 0.24 ±0.07 0.63 ±0.06∗∗ 0.33 ±0.04 2.03 ±0.29∗∗
∗P<0.05, ∗∗P<0.01 versus respective age-matched LETO controls. Data are mean ± SEM, n = 8.
endothelial layer (Figure 5). In carotid artery, however, only
NOS content was elevated and HO remained unchanged
(Figure 6).
Both the aorta and carotid artery of OLETF exhibited
decreased eNOS protein expression (Figures 7 and 8), sug-
gesting impaired NOS system responsible for endothelium
dysfunction in large vessels of the obese diabetic rats.
3.4. Vasodilation and Intima Changes after Insulin Admin-
istration. Daily insulin dose was adjusted around 20 to
25IU/kg/d to maintain the blood glucose of GK at the range
of4to6mmol/Lfor20days,withoneGKoutofeightdiedof
hypoglycemia. Insulin injection in GK resulted in a marked
reduction in blood glucose and elevation in serum insulin.
The body weight, levels of glucose and insulin of GK injected
with protamine zinc insulin at sacriﬁce were 422 ± 10g,
4.0±1.9mmol/L,and18.5±5.4μg/L(n = 7),versus368±7g,
19.5±0.8mmol/L, and 3.3±0.6μg/L in control GK (n = 8),
respectively. The body weight, levels of glucose and insulin
in control Wistar were 409 ± 8g, 5.6 ± 0.4mmol/L, and
4.2 ± 0.5μg/L (n = 8), respectively.
Insulin administration reduced endothelium-dependent
vasodilation with no change in endothelium-independent
vasodilation (Figure 9(a)). Insulin also induced intima hy-
perplasia in both aorta and carotid artery. Subendothelial
thickening with plenty of collagen ﬁbers was the main
characteristic of insulin-induced hyperplasia (Figures 9(b)
and 9(c)).
3.5. Vessel Production of NO and ROS. Vessel production of
NO was signiﬁcantly increased in GK, which was reduced
after insulin administration (relative NO production values
of Wistar, GK, and GK+Insulin were 1.1 ± 0.2, 2.8 ± 0.5,
0.4 ± 0.2, resp., n = 4; GK versus Wistar and GK + Insulin,
P<0.01). The production of ROS in GK was also higher
than control (relative ROS production values of Wistar, GK,
andGK+Insulinwere1.2±0.1,6.5±1.3,and1.1±0.2,resp.,
n = 4; GK versus Wistar, P<0.01).
3.6. Hyperglycemia/Hyperosmolarity on Vessel eNOS/HO-
1. Protein expressions of eNOS and HO-1, both related
to enhanced vasodilation, were upregulated in aorta
after hyperglycemia/hyperosmolarity incubation for 5h
(Figure 10).
4. Discussion
The main ﬁndings in the present study are (1) the lean GK
hadmarkedhyperglycemiawithwell-preservedendothelium
function at early and later stages, while the obese OLETF
showed mild hyperglycemia but signiﬁcant endothelium
dysfunction and hyperinsulinemia at early stage; (2) the GK
showed elevated vessel eNOS and HO protein and OLETF
decreased vessel eNOS; (3) insulin injection corrected hyper-
glycemia in GK but induced endothelium dysfunction and
intima hyperplasia; (4) hyperglycemia/hyperosmolarity in
vitro upregulated vasodilating eNOS/HO-1.
Endothelium dysfunction has been considered to con-
tribute to the increased coronary artery disease in type 2
diabetic patients, and hyperglycemia is suggested to be one
of the risk factors contributing to endothelium dysfunction.
However, controversies exist on endothelium dysfunction in
both type 1 and lean type 2 diabetic animals, especially in
early stages [7, 10–15, 22–26]. The present ﬁndings in GK
suggest that hyperglycemia per se seems not likely the cause
for vessel dysfunction in diabetic rats at early or later stages.
Rather, persistent hyperglycemia may be a preconditioning
stimulus, inducing eNOS and HO that can exert both
vasodilation as well as cardiovascular protection. Our results
are supported by evidence from other groups showing that
high glucose can induce eNOS elevation in GK aorta [15, 22]
and in endothelial cells from human aorta [27].
Metabolic syndrome is highly prevalent in the modern
society, with characteristics of central obesity, diabetes, hy-
perinsulinemia, hypertension, and dyslipidemia. Although
theindividualcomponentsofmetabolicsyndromeareclearly
associated with increased coronary disease, there are also
reports demonstrating that diabetes patients without met-
abolic syndrome have no greater prevalence of coronary
artery disease [28, 29], indicating less importance of iso-
lated hyperglycemia in macrovascular complications. In
the present study, OLETF demonstrated typical metabolic
syndromethatmayberesponsibleforvesseldysfunction.Itis6 Experimental Diabetes Research
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Figure 2: Endothelium-dependent and endothelium-independent vasodilation of the aorta (AO) and carotid artery (CA) in Goto-Kakizaki
rats (GK) and age-matched control Wistar rats. Data are mean ± SEM, n = 16–24 segments. ∗P<0.05, ∗∗P<0.01 versus respective
controls.Experimental Diabetes Research 7
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Figure 3: Endothelium-dependent and endothelium-independent vasodilation of the aorta (AO) and carotid artery (CA) in Otsuka Long-
Evans Tokushima Fatty rats (OLETF) and age-matched control Long-Evans Tokushima Otsuka rats (LETO). Data are mean ± SEM, n =
10–14 segments. ∗P<0.05, ∗∗P<0.01 versus respective controls.8 Experimental Diabetes Research
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Figure 4: Aorta responses to acetylcholine (ACh) and phenylephrine (PE) in the presence of nitric oxide synthase blocker, Nω-nitro-
L-arginine methyl ester (L-NAME) or heme oxygenase blocker, protoporphyrin IX Zinc (II) (ZnPPIX) in OLETF: Otsuka Long-Evans
Tokushima Fatty rat; LETO: Long-Evans Tokushima Otsuka rat; GK: Goto-Kakizaki rat. (a) representative tracings of vessel tension in
3-month-old OLETF and 12-month-old GK, respectively. (b) Relaxation of 12-month-old rat aorta rings to 1μm o l / LA C hb e f o r ea n da f t e r
NOS and/or HO blockade. Data are mean ± SEM, n = 10–12 segments. ∗∗P<0.01 versus respective controls.
noticeable that hyperinsulinemia was present at early stages
of the 3-month-old OLETF, when endothelium dysfunction
was already present. Other risk factors such as signiﬁcantly
higher LDL-cholesterol and triglyceride may contribute to
the sustained endothelium dysfunction albeit the decline
of insulin in the later stage of OLETF. Taking together
the ﬁndings that OLETF with metabolic syndrome had
mild hyperglycemia but early endothelium dysfunction,
while GK without metabolic syndrome showed higher blood
glucose but enhanced vasodilation, it is suggested that the
conventional risk factors, such as obesity, hyperinsulinemia,
and dyslipidemia, rather than hyperglycemia, contribute to
the increased cardiovascular events in type 2 diabetes.
In the 12-month-old GK aorta, we observed a non-NO-
dependent acetylcholine-induced relaxation (ranging from
3% to 15%, with 6.4% in average) that could be abrogated by
simultaneous inhibition of HO and NOS. This phenomenon
could also be observed in type 1 diabetic model rats and was
especially marked in GK with severe hyperglycemia [10, 11].
Heme oxygenase is a number of heat shock protein
(hsp) family (also called hsp 32) that has antioxidant and
cytoprotective properties. When breaking down heme, HO
creates carbon monoxide (CO), another endogenous va-
sodilator that stimulates soluble guanylate cyclase in smooth
muscle cells and regulates vascular tension in a manner
similar to NO [30]. Our study found that exposure toExperimental Diabetes Research 9
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Figure 5:Immunoﬂuorescentcolocalizationofendothelialnitricoxidesynthase(eNOS,red)andinducibleNOS(iNOS,green),constitutive
heme oxygenase (HO-2, green) and inducible HO (HO-1, red) in aorta (AO) from control Wistar and Goto-Kakizaki rats (GK). The
endothelial layer is on the left side and perivascular layers on the right side. Bar = 20μm. Data are presented as mean ± SEM, n = 6-7.
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hyperglycemia/hyperosmolarity could induce upregulation
of eNOS and HO-1, supporting the hypothesis that in addi-
tiontoNOS/NOsystem,HO/COsystemmayalsocontribute
to the enhanced endothelium-dependent relaxation in GK.
The increased function of both NOS/NO and HO/CO
systems may be a compensative response to hyperglycemia,
w h i c hh a sb e e ns u g g e s t e da sah a r m f u ls t i m u l u st ov a r i o u s
kinds of tissues and organs. In GK, hyperglycemia resulted10 Experimental Diabetes Research
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Figure 6:Immunoﬂuorescentcolocalizationofendothelialnitricoxidesynthase(eNOS,red)andinducibleNOS(iNOS,green),constitutive
heme oxygenase (HO-2, green) and inducible HO (HO-1, red) in carotid artery (CA) from control Wistar and Goto-Kakizaki rats (GK). Bar
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in ROS and iNOS elevation and thus oxidative stress to
endothelium. We have found that acute hyperglycemia
(10min) was detrimental to endothelium function with in-
creased ROS production [31]; however, as the hyperglycemia
stimulation sustained (5h), it induced endogenous antiox-
idants including eNOS and HO [10]. Thus, hyperglycemia
can be both a stress and a preconditioning factor that in-
ducing endogenous protection. These ﬁndings may have
some implications for the failure of clinical trials with
antioxidants in diabetes, a way of treatment based on the
rationale of oxidative stress-induced damage in diabetes
[32]. The ﬁndings that hyperosmolarity stimulation was alsoExperimental Diabetes Research 11
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controls.
eﬀective on inducing eNOS/HO-1 as hyperglycemia suggests
that hyperglycemia may act partly through hyperosmolarity
in upregulating cardiovascular eNOS/HO-1 [6, 7]. However,
further investigations are necessary to clarify the novel
mechanisms of cardiovascular adaptation to hyperglycemia.
It is also interesting to ﬁnd that metabolic correction
with insulin reversed the enhanced endothelium function in
GK, which may be due to the downregulation of eNOS/HO-
1a sw ef o u n dp r e v i o u s l y[ 10]. Insulin administration also
resulted in intima hyperplasia, especially subendothelial12 Experimental Diabetes Research
0
0.5
1
1.5
iNOS eNOS HO-2 HO-1
R
e
l
a
t
i
v
e
d
e
n
s
i
t
y
NOS NOS HO HO
iNOS iNOS HO-2 HO-2
eNOS eNOS HO-1 HO-1
∗
∗∗ ∗
CA CA CA CA
CA
LETO
OLETF
LETO OLETF LETO OLETF
LETO OLETF LETO OLETF
12 months
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(LETO) and Otsuka Long-Evans Tokushima Fatty rats (OLETF). Bar = 20μm. Data are presented as mean ± SEM, n = 6-7. ∗P<0.05 versus
respective controls.
thickening that may impede NO diﬀusion into smooth
muscle to induce relaxation. The insulin-induced intima
hyperplasia was also found in type 1 diabetes after balloon
injuryinrats[33]andmayberesponsibleforacceleratedcor-
onary restenosis in human beings [34, 35]. Thus, our ﬁnd-
ings are consistent with the above reports, suggesting the
metabolic correction by insulin could result in an unin-
tentional hyperinsulinemia and intima hyperplasia thatExperimental Diabetes Research 13
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can be detrimental to endothelial function and vascular
atherosclerosis. This might explain partly for the unfavorable
or absence of favorable eﬀects of intensive glucose control on
cardiovascular outcomes in the ACCORD and ADVANCE
or the Veterans Aﬀairs Diabetes Trial (VADT), which use
more insulin and insulin secretagogues frequently [1–3]a s
compared with the standard therapy.
On the other hand, the Diabetes Control and Compli-
cations Trial/Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) studies have shown that in
type1diabeticpatients,intensiveglucosecontrolreducedthe
incidence of both micro- and macrovascular complications
in the long-term during followup. The beneﬁt was even
present after the glucose returned to control level. Thus
the prior glucose control exerted the beneﬁt by way of
“glucose memory” [36, 37]. The results from UKPDS also
showed long-term beneﬁts of a “memory” of intensive
glucosecontrolinmacrovascularoutcomesintype2diabetic
patients [38, 39]. However, some assumptions have been put
forward to explain the reasons for the apparent disparity,
includingthediﬀerenttargetsofglucosecontrol,weightgain,
frequenthypoglycemia,diﬀerentantihypertensiveregiments,
multiple risk factors, and the stages of diabetes when tight
glucose control is initiated [2, 3, 36, 37, 40–42]. Compared
with ACCORD and ADVANCE or VADT, DCCT/EDIC and
UKPDS started glucose control at relatively early stages of
diabetes with gradual achievement of target HbA1c, which
were higher than that of ACCORD and ADVANCE or VADT
at the end of the trials. The frequent use of insulin and
secretagogues proved to be eﬀective in rapid achieving of
the target HbA1c in ACCORD but with more adverse events
such as hypoglycemia. Our ﬁndings indicate that when
lowering blood glucose, insulin administration abrogates the
adaptive mechanisms of long-term severe hyperglycemiaand
promotes intima hyperplasia at the same time. The death
from accidental hypoglycemia is possibly another reason of
deathduringintensivebloodcontrol.Otherriskfactors,such
as dyslipidemia and obesity in OLETF or weight gain in in-
sulin injected GK, may also contribute to the endothelium
dysfunction. Therefore, gradual glucose lowering combined
withamoreintensiveapproachtocontrolthemodiﬁablerisk
factors is necessary to minimize associated morbidity and
mortality in type 2 diabetes.
5. Conclusion
Both endothelium-dependent and smooth muscle-depend-
ent vasodilation in aorta and carotid artery were enhanced
in lean diabetic GK, but impaired in obese diabetic OLETF
at early and later stages. Our data suggest that large ves-
sels may adapt to sustained hyperglycemia/hyperosmolarity
and developed a compensative way through upregulating
eNOS/HO for vasodilation, while the clustering risk factors
including marked obesity, hyperinsulinemia, and hypertri-
glyceridemia other than hyperglycemia are involved in vessel
dysfunctionoftheobeseOLETF.However,theexacteﬀectsof
high glucose and insulin on vessel function and their mech-
anisms need further investigations.
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